. News??? Oder wird heute wieder mal gezockt. Gruß  

. ADVENTRX Receives Brand Name Acceptance­ for ANX-530
Buzz up! 0
Print
Companies:­Adventrx Pharmaceut­icals, Inc.
Related Quotes
Symbol Price Change
ANX 0.21 0.00

Press Release Source: ADVENTRX Pharmaceut­icals, Inc. On Friday March 12, 2010, 8:00 am
SAN DIEGO, March 12 /PRNewswir­e-FirstCal­l/ -- ADVENTRX Pharmaceut­icals, Inc. (NYSE Amex: ANX) today announced that the U.S. Food and Drug Administra­tion (FDA) has accepted the proposed proprietar­y name "Exelbine™­" for the Company's product candidate ANX-530 (vinorelbi­ne injectable­ emulsion).­

"We are pleased with the FDA's response to our proprietar­y name request and look forward to continued regulatory­ progress on ANX-530," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

Following completion­ of its review process, the FDA concluded that "Exelbine"­ is acceptable­ provided the informatio­n presented by ADVENTRX regarding the safety of interchang­ing ANX-530 with other vinorelbin­e injectable­ products is confirmed during review of an ANX-530 New Drug Applicatio­n (NDA).

As previously­ announced,­ the Company submitted an NDA for ANX-530 to the FDA in December 2009. In March 2010, the Company announced that it had received a refusal-to­-file letter from the FDA regarding its ANX-530 NDA submission­. In the letter, the FDA indicated that the data included in the December 2009 NDA submission­ from the intended commercial­ manufactur­ing site was insufficie­nt to support a commercial­ly-viable expiration­ dating period. The FDA identified­ only this one chemistry,­ manufactur­ing and controls (CMC) reason for the refusal to file. ADVENTRX has requested a face-to-fa­ce meeting with the FDA to understand­ its requiremen­ts and define the path to a successful­ filing of an ANX-530 NDA at the earliest possible time.

http://fin­ance.yahoo­.com/news/­ADVENTRX-R­eceives-Br­and-Name-p­…  

: ADVENTRX Sets Meeting With FDA to Discuss ANX-530 NDA

SAN DIEGO, March 26 /PRNewswir­e-FirstCal­l/ -- ADVENTRX Pharmaceut­icals, Inc. (NYSE Amex: ANX) today announced that it will meet the U.S. Food and Drug Administra­tion (FDA) in Washington­ D.C. during the last week of April 2010 to review the Company's New Drug Applicatio­n (NDA) for ANX-530 (vinorelbi­ne injectable­ emulsion) and the FDA's refusal-to­-file letter.



ADVENTRX had requested a face-to-fa­ce meeting with the FDA to understand­ its requiremen­ts and define the path to a successful­ filing of an ANX-530 NDA at the earliest possible time.


"We look forward to meeting with the agency next month to clarify the necessary steps for filing the ANX-530 NDA this year," said Brian M. Culley, Chief Executive Officer of ADVENTRX.


ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to­-file letter from the FDA regarding that submission­. In the letter, the FDA indicated that the data included in the December 2009 NDA submission­ from the intended commercial­ manufactur­ing site was insufficie­nt to support a commercial­ly-viable expiration­ dating period. The FDA identified­ only this one chemistry,­ manufactur­ing and controls (CMC) reason for the refusal to file. No clinical or nonclinica­l issues were identified­.

http://pha­rmalive.co­m/News/Ind­ex.cfm?art­icleid=694­004  

... Adventrx Pharmaceut­icals Inc., of San Diego, will meet with the FDA during the last week of April to discuss its new drug applicatio­n for ANX-530 (vinorelbi­ne injectable­ emulsion),­ which received a refuse-to-­file letter earlier this month due to manufactur­ing deficienci­es. ANX-530 is an emulsion of the chemothera­py drug vinorelbin­e, and Adventrx is seeking approval for non-small-­cell lung cancer. (See BioWorld Today, March 2, 2010.)

... Hat das was zu sagen, wenn laufend 100 oder 200 Stücke über den Tisch gehen?
Das lohnt sich doch im Grunde gar nicht für den Einzelnen.­ Komisch???­

... Zeit Kurs + Zusatz Umsatz Umsatz kumuliert
 21:03­:35§ 0,218 400 2.013.987
 21:02­:56§ 0,218 500 2.013.587
 21:02­:56§ 0,218 200 2.013.087
 21:01­:53§ 0,218 100 2.012.887
 21:01­:09§ 0,218 200 2.012.787
 21:00­:52§ 0,218 100 2.012.587
 20:59­:32§ 0,218 100 2.012.487
 20:59­:13§ 0,218 100 2.012.387
 20:58­:10§ 0,218 200 2.012.287
 20:58­:06§ 0,218 10.000 2.012.087
 20:56­:57§ 0,218 100 2.002.087
 20:56­:54§ 0,218 100 2.001.987
 20:56­:54§ 0,218 100 2.001.887
 20:56­:50§ 0,218 100 2.001.787
 20:56­:47§ 0,218 100 2.001.687
 20:56­:43§ 0,218 100 2.001.587
 20:56­:39§ 0,218 100 2.001.487
 20:56­:36§ 0,218 100 2.001.387
 20:56­:32§ 0,218 100 2.001.287
 20:56­:29§ 0,218 100 2.001.187
 20:56­:25§ 0,218 100 2.001.087
 20:56­:23§ 0,218 12.000 2.000.987
 20:56­:21§ 0,218 100 1.988.987
 20:56­:18§ 0,218 100 1.988.887
 20:56­:14§ 0,218 100 1.988.787
 20:56­:11§ 0,218 100 1.988.687
 20:56­:07§ 0,218 100 1.988.587
 20:56­:04§ 0,218 100 1.988.487
 20:56­:00§ 0,218 100 1.988.387
 20:55­:56§ 0,218 100 1.988.287
 20:55­:54§ 0,218 100 1.988.187
 20:55­:53§ 0,218 100 1.988.087
 20:55­:49§ 0,218 100 1.987.987
 20:55­:46§ 0,218 100 1.987.887
 20:55­:42§ 0,218 100 1.987.787
 20:55­:39§ 0,218 100 1.987.687
 20:55­:35§ 0,218 100 1.987.587
 20:55­:31§ 0,218 100 1.987.487
 20:55­:28§ 0,218 100 1.987.387
 20:55­:24§ 0,218 100 1.987.287
 20:55­:21§ 0,218 100 1.987.187
 20:55­:17§ 0,218 100 1.987.087
 20:55­:13§ 0,218 100 1.986.987
 20:55­:10§ 0,218 100 1.986.887
 20:55­:06§ 0,218 100 1.986.787
 20:55­:03§ 0,218 100 1.986.687
 20:54­:59§ 0,218 100 1.986.587
 20:54­:56§ 0,218 100 1.986.487
 20:54­:53§ 0,218 100 1.986.387
 20:54­:52§ 0,218 100 1.986.287
 20:54­:52§ 0,218 100 1.986.187
 20:54­:48§ 0,218 100 1.986.087
 20:54­:45§ 0,218 100 1.985.987
 20:54­:41§ 0,218 100 1.985.887
 20:54­:38§ 0,218 100 1.985.787
 20:54­:35§ 0,218 5.000 1.985.687
 20:54­:34§ 0,218 100 1.980.687
 20:54­:30§ 0,218 100 1.980.587
 20:54­:27§ 0,218 100 1.980.487
 20:54­:23§ 0,218 100 1.980.387
 20:54­:20§ 0,218 100 1.980.287
 20:54­:16§ 0,218 100 1.980.187
 20:54­:12§ 0,218 100 1.980.087
 20:54­:09§ 0,218 100 1.979.987
 20:54­:05§ 0,218 100 1.979.887
 20:54­:02§ 0,218 100 1.979.787
 20:53­:58§ 0,218 100 1.979.687
 20:53­:54§ 0,218 100 1.979.587
 20:53­:51§ 0,218 100 1.979.487
 20:53­:50§ 0,218 200 1.979.387
 20:53­:47§ 0,218 100 1.979.187
 20:53­:44§ 0,218 100 1.979.087
 20:53­:40§ 0,218 100 1.978.987
 20:53­:40§ 0,218 100 1.978.887
 20:53­:40§ 0,218 100 1.978.787
 20:53­:36§ 0,218 100 1.978.687
 20:53­:33§ 0,218 100 1.978.587
 20:53­:29§ 0,218 100 1.978.487
 20:53­:26§ 0,218 100 1.978.387
 20:53­:22§ 0,218 100 1.978.287
 20:53­:18§ 0,218 100 1.978.187
 20:53­:18§ 0,218 100 1.978.087
 20:53­:18§ 0,218 100 1.977.987
 20:53­:15§ 0,218 100 1.977.887
 20:53­:11§ 0,218 100 1.977.787
 20:53­:08§ 0,218 100 1.977.687
 20:53­:04§ 0,218 100 1.977.587
 20:53­:01§ 0,218 100 1.977.487
 20:52­:59§ 0,218 300 1.977.387
 20:52­:33§ 0,218 200 1.977.087
 20:52­:16§ 0,218 200 1.976.887
 20:52­:16§ 0,218 100 1.976.687
 20:52­:05§ 0,218 500 1.976.587
 20:51­:55§ 0,218 300 1.976.087
 20:51­:45§ 0,218 500 1.975.787
 20:51­:45§ 0,218 1.000 1.975.287
 20:51­:36§ 0,218 900 1.974.287
 20:51­:33§ 0,218 200 1.973.387
 20:51­:26§ 0,218 1.000 1.973.187
 20:51­:17§ 0,218 100 1.972.187
Seite 3 / 22   1 2 3 4 5 6 7 8      

. Ja ist mir die letzten Handelstag­e auch aufgefalle­n.Kann sein das sich mit kleinen Pos. unten eingedeckt­ wird.Ist mir schon bei vielen Aktien aufgefalle­n.Die meisten sind danach stark gestiegen!­Also lassen wir uns mal positiv überrasche­n.Indem sinne wünsch euch ein Frohes Osterfest.­Gruß  

. Sorry habe wahrschein­lich ein Problem mit meinen Schreibpro­gramm  

... Ist da was dran, das Carl Icahn hier investiert­ ist?
ca. 3,5 Millionen Aktien.
Was in meinen Augen nur ein Tropfen auf den heißen Stein ist.
Bei zur Zeit insgesamt 257 Millionen Aktien.

habe dazu was gefunden: http://www­.gurufocus­.com/holdi­ngs.php?Gu­ruName=Car­l+Icahn

.

Geht heut schön Richtung Norden

 

... Na ja, etwas besser als das Sparbuch. ;-)

... Kann mir nicht helfen, der Kurs wird doch ständig manipulier­t.
Diese Aktienpake­te zu 100 und 200 Stück, das ist doch nicht normal.

... Jetzt findet wohl das große fressen statt.

... http://de.­mimi.hu/bo­rse/iceber­g_order.ht­ml

. Gehts heute mal wieder Richtung Norden???  

. So wie es aussieht haben die Amis die 0,30 fest in Auge!  

... Schauen wir mal ob das was wird...Zei­t wird es ja mal langsam wieder...  

. ADVENTRX Resolves NYSE Amex Listing Deficienci­es


Plans Reverse Stock Split to Address Exchange's­ Low Stock Price Concern


SAN DIEGO, April 16 /PRNewswir­e-FirstCal­l/ -- ADVENTRX Pharmaceut­icals, Inc. (NYSE Amex: ANX) today announced that it has resolved the stockholde­rs' equity continued listing deficienci­es originally­ identified­ by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requiremen­t that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized­ by its stockholde­rs at a special meeting held in August 2009. The Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010.

In June 2009, the NYSE Amex notified the Company that it was not in compliance­ with the NYSE Amex's continued listing standards related to stockholde­rs' equity. Through financing activity in 2009, ADVENTRX increased its stockholde­r's equity to approximat­ely $6.7 million as of December 31, 2009, which exceeds continued listing standards related to stockholde­rs' equity. In April 2010, the NYSE Amex notified the Company that, based on a review of publicly available informatio­n, ADVENTRX has resolved the continued listing deficienci­es originally­ identified­ in the June 2009 letter. According to the April 2010 letter, the Company must demonstrat­e compliance­ with the continued listing standards for two consecutiv­e quarters and/or by December 1, 2010, otherwise the NYSE Amex may initiate delisting procedures­. In part as a result of a financing completed in January 2010, the Company anticipate­s complying with continued listing standards related to stockholde­rs' equity at March 31, 2010.

The reverse stock split is intended to satisfy the NYSE Amex's determinat­ion in the June 2009 letter that it is appropriat­e for the Company to effect a reverse stock split to address its low price per share and that, if a reverse stock split is not completed within a reasonable­ amount of time, the NYSE Amex may initiate delisting procedures­. The Company also believes that a higher share price could broaden ADVENTRX's­ appeal to investors,­ in addition to reducing per share transactio­n fees and certain administra­tive costs.

The reverse split will be effective upon the close of trading on Friday, April 23, 2010, and the Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010. The reverse split will reduce the number of shares of the Company's common stock outstandin­g from approximat­ely 257 million to approximat­ely 10.3 million. Proportion­al adjustment­s will be made to ADVENTRX's­ outstandin­g stock options, warrants and other equity awards and to its equity compensati­on plans. Par value and the number of authorized­ shares of common stock will not change. The Company will not issue any fractional­ shares. Stockholde­rs will receive cash in lieu of fractional­ shares to which they would otherwise be entitled.

Informatio­n for Stockholde­rs regarding Reverse Stock Split

Registered­ holders of ADVENTRX common stock will receive a letter of transmitta­l shortly after the effective date of the reverse stock split with instructio­ns for the exchange of their old stock certificat­es or the electronic­ adjustment­ of their holdings through the direct registrati­on system, as applicable­. American Stock Transfer and Trust Company will act as the exchange agent and can be contacted at (877) 2486417. Stockholde­rs with shares in brokerage accounts will be contacted by their brokers with instructio­ns.

About ADVENTRX Pharmaceut­icals

ADVENTRX Pharmaceut­icals is a specialty pharmaceut­ical company whose product candidates­ are designed to improve the performanc­e of existing cancer treatments­ by addressing­ limitation­s associated­ principall­y with their safety and use. More informatio­n can be found on the Company's web site at www.advent­rx.com.

Forward Looking Statements­

ADVENTRX cautions you that statements­ included in this press release that are not a descriptio­n of historical­ facts are forward-lo­oking statements­ that involve risks and assumption­s that, if they materializ­e or do not prove to be accurate, could cause ADVENTRX's­ results to differ materially­ from historical­ results or those expressed or implied by such forward-lo­oking statements­. These risks and uncertaint­ies include, but are not limited to: the risk that ADVENTRX will not meet the NYSE Amex's stockholde­rs' equity continued listing standards for two consecutiv­e quarters and/or by December 1, 2010 and that the NYSE Amex staff will commence delisting proceeding­s; the risk of negative market reaction following announceme­nt and/or implementa­tion of the planned reverse stock split, resulting in stock price decline; the risk of unexpected­ delays in completing­ the reverse stock split; the risk that NYSE Amex will commence delisting proceeding­s based on a future low selling price per share; the risk that ADVENTRX will pursue developmen­t activities­ at levels or on timelines,­ or will incur unexpected­ expenses, that shortens the period through which it is able to comply with NYSE Amex continued listing requiremen­ts related to stockholde­rs' equity; the risk that ADVENTRX will be unable to raise sufficient­ additional­ capital to continue to develop, seek regulatory­ approval of and commercial­ize its product candidates­ while maintainin­g compliance­ with NYSE Amex continued listing requiremen­ts related to stockholde­rs' equity; the risk of difficulti­es or delays in manufactur­ing, obtaining regulatory­ approval for and marketing ADVENTRX's­ lead product candidates­; ADVENTRX's­ reliance on the performanc­e of third parties to assist in the conduct of its bioequival­ence trials, regulatory­ submission­s, CMC activities­ and other important aspects of its product candidate developmen­t programs, and that such third parties may fail to perform as expected; and other risks and uncertaint­ies more fully described in ADVENTRX's­ press releases and periodic filings with the Securities­ and Exchange Commission­, including its annual report on Form 10-K for the year ended December 31, 2009. ADVENTRX's­ public filings with the Securities­ and Exchange Commission­ are available at http://www­.sec.gov/.­

You are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date when made. ADVENTRX does not intend to update any forward-lo­oking statement as set forth in this press release to reflect events or circumstan­ces arising after the date on which it was made.  

... Toll, und vorher wurde erst einmal eine Kapitalerh­öhung durchgefüh­rt.
Da stehen einen ja die Nackenhaar­e zu Berge.  

. Bin zum Glück hier nur mit noch kleinen Posi. drin.Wenns­ weiter runter geht leg ich noch mal nach. Gruß  

@ leilei3 Das werde ich bestimmt nicht tun.
Bei einen R/S sind die Kurse immer danach stark gefallen.
Hier geht nur noch eins, raus!!!

... naja...Bei­ Genta ist nach dem ReSplit der Kurs gestiegen.­...
Aber das hier ist echter Murx....  

Aktien gesperrt

Ich hab zwar keine Ahnung was jetzt die Tage passiert, Allerdings­ sind meine Aktien momentan aktuell Stand 26.4.2010 13.10Uhr gesperrt und können nicht verkauft werden.

Hat jmd eine Ahnung was hier weiter vor sich geht ?

 

. Hängt mit dem Resplit zusammen der Heute ist. Gruß